PubMed Daily Triage Digest — 2026-07-16

Run: 2026-07-16-attempt1-20260716T090000Z | Pipeline v1.3 | Window: 2026-07-15 → 2026-07-16

📊 Coverage Summary

*humans[MeSH] filter applied

🔴 HIGH Priority Articles (Score ≥ 8)

1. PAPOLA-Mediated Hyperactive Polyadenylation Drives AML via Metabolic Reprogramming [Score: 9]

PMID: 42457944 | Journal: Nat Cancer | Topic: Hematologic Malignancies Authors: Guo S, Zou Y, Zhang C, Han H, et al. (Lin S, corresponding) DOI: 10.1038/s43018-026-01190-7

PAPOLA-driven hyperactive polyadenylation promotes leukemia stem cell self-renewal in AML through the GSTM2-HNE-DLD metabolic axis. Cordycepin-mediated PAPOLA inhibition suppresses leukemogenesis across primary AML samples, cell lines, and mouse models.

Why it matters: Nature Cancer reveals a novel oncogenic mechanism linking RNA polyadenylation to AML cancer metabolism—with an identified druggable target (PAPOLA inhibition via cordycepin) and potential for biomarker development. This establishes hyperactive polyadenylation as a core oncogenic pathway with therapeutic implications.

2. SmartAlert ML-CDS Reduces Inpatient CBC Utilization by 15% in RCT [Score: 9]

PMID: 42453199 | Journal: NEJM AI | Topic: CBC/ML Diagnostics Authors: Liang AS, Amrollahi F, Jiang Y, Corbin CK, et al. (Chen JH, corresponding) DOI: 10.1056/aics2501086

A machine learning CDS system predicting stable CBC results reduced repetitive CBC orders by 15% (1.54 vs 1.82, P<0.01) in a randomized pilot across 9,270 admissions at two Stanford hospitals without adverse safety outcomes.

Why it matters: NEJM AI publishes a prospective RCT demonstrating safe, clinically meaningful reduction in unnecessary CBC testing via ML. This is a landmark deployment case study with detailed implementation and governance lessons directly actionable for lab utilization programs.

3. 6-mRNA Liquid Biopsy Achieves AUC 0.91 for PLC-Positive Gastric Cancer [Score: 8]

PMID: 42457866 | Journal: NPJ Precis Oncol | Topic: Early Cancer Detection Authors: Ding P, Guo H, Ma W, Wu J, et al. (Zhao Q, corresponding) DOI: 10.1038/s41698-026-01531-w

Six mRNA biomarkers (NOX1, CHEK1, BUB1, NEK2, PRC1, SLCO1B3) integrated into a Risk Stratification Assessment model achieved AUC 0.87-0.91 in peripheral blood for detecting peritoneal lavage cytology-positive gastric cancer, with high-risk patients showing significantly lower 5-year survival.

Why it matters: NPJ Precision Oncology validates a non-invasive transcriptomics-based liquid biopsy for a diagnostically challenging gastric cancer phenotype indicating early peritoneal metastasis. The prospective multicenter design and registered clinical trial registration strengthen clinical credibility.

4. 3-Day Trispecific CAR-T from Whole Blood: Stem-Like Phenotype, Equivalent Cytotoxicity [Score: 8]

PMID: 42458494 | Journal: J Transl Med | Topic: Novel Therapeutics Authors: Vignola I, Prochazkova M, Shao L, et al. (Highfill SL, corresponding, NIH) DOI: 10.1186/s12967-026-08306-8

NIH investigators developed a GMP-compliant 3-day manufacturing process for CD19-CD20-CD22 trispecific CAR T-cells directly from whole blood, producing products with >95% viability, 53% transduction efficiency, stem-like phenotype, and cytotoxicity equivalent to standard 7-day products.

Why it matters: A streamlined, potentially decentralized CAR-T manufacturing approach from NIH directly addresses cost and accessibility barriers for trispecific B-cell malignancy CAR-T therapy, while generating a phenotypically superior (more stem-like) product.

5. Marnetegragene Autotemcel: First FDA-Approved Gene Therapy for LAD-I [Score: 8]

PMID: 42455480 | Journal: Mol Diagn Ther | Topic: Rare Diseases 🏁 Authors: Fung S DOI: 10.1007/s40291-026-00863-4

Marnetegragene autotemcel (KRESLADI™, Rocket Pharmaceuticals) received first US FDA approval in March 2026 for pediatric severe leukocyte adhesion deficiency type I (LAD-I) without an HLA-matched sibling donor—the first gene therapy for this rare, often fatal primary immunodeficiency.

Why it matters: Regulatory milestone—the first FDA-approved lentiviral HSC gene therapy for a pediatric primary immunodeficiency with high mortality risk. Significant for rare disease gene therapy pipelines and validates the autologous HSC gene therapy platform for ITGB2-related disorders.

6. RadFabric: Agentic AI Orchestrating 14 CXR Models Achieves AUC 85.18% [Score: 8]

PMID: 42457975 | Journal: NPJ Digit Med | Topic: AI/ML Diagnostics Authors: Chen W, Dong Y, Ding Z, et al. (Li X, corresponding; MGH/Harvard) DOI: 10.1038/s41746-026-02994-8

RadFabric, an agentic AI system orchestrating 14 open-source CXR analytics models via an Anatomical Interpretation Agent and trainable reasoning agent, achieves AUC 85.18% on MIMIC-CXR—outperforming all state-of-the-art CXR models—with particular gains in rare pathologies through interpretable reasoning.

Why it matters: NPJ Digital Medicine introduces a novel extensible agentic AI architecture for radiology that achieves SOTA performance on a major public benchmark while providing interpretable, anatomically-grounded reasoning. Demonstrates a scalable framework for integrating heterogeneous AI models.

7. Plasma Multi-Omics Identifies DEFA1 as Predictor of Neoadjuvant Immunotherapy Failure in ESCC [Score: 8]

PMID: 42458504 | Journal: Mol Cancer | Topic: Precision Oncology Authors: Xiao C, Deng Z, Zhang G, et al. (He J, corresponding; CICAMS) DOI: 10.1186/s12943-026-02733-3

Longitudinal plasma proteomics and metabolomics in locally advanced ESCC identified DEFA1 as a validated negative predictor of pathological complete response after neoadjuvant immunochemotherapy, validated in 93 patients, with mechanistic evidence linking DEFA1 to MDSC-mediated immunosuppression.

Why it matters: Molecular Cancer publication with multi-cohort validation of an actionable biomarker and mechanistic target for immunotherapy resistance in ESCC—a cancer with high mortality in Asia and limited precision medicine tools.

8. MAIT Cell 3-Marker Panel Achieves AUC 0.85 for Pre-Transplant GI aGVHD Prediction [Score: 8]

PMID: 42458215 | Journal: Br J Haematol | Topic: Precision Oncology / Hematologic Malignancies Authors: Mengge G, Rongqi C, Jun K, et al. (Xiaosu Z, corresponding; Peking University) DOI: 10.1111/bjh.70683

A 3-marker MAIT cell panel (CCR2, IL-4, IL-17A) measured by spectral flow cytometry on PBSC grafts achieves AUC 0.85 for pre-transplant prediction of GI acute graft-versus-host disease after allo-HSCT.

Why it matters: Prospective registered clinical trial (ChiCTR2500095349) demonstrating a validated pre-transplant biomarker panel for GI aGVHD—a major cause of transplant mortality—enabling precision risk stratification before allo-HSCT.

9. Venetoclax-Enhanced RIC Shows 72.5% 1-Year PFS in Older High-Risk AML/MDS Phase II [Score: 8]

PMID: 42457583 | Journal: Br J Haematol | Topic: Hematologic Malignancies / Novel Therapeutics Authors: Gao J, Qiu H, Tong Y, et al. (Yang J, corresponding; Shanghai General Hospital) DOI: 10.1111/bjh.70690

Phase II trial of venetoclax-enhanced RIC (VEN-RIC) in 50 older (median age 62) high-risk AML/MDS patients undergoing allo-PBSCT showed 1-year PFS 72.5%, OS 73.8%, NRM 10.6%, with TP53 mutation as the strongest predictor of worse outcomes.

Why it matters: Phase II evidence for a rationale-driven venetoclax-enhanced conditioning approach in an underserved population (older, high-risk myeloid malignancy), with encouraging survival data warranting randomized investigation.

🟡 MEDIUM Priority Highlights (Score 5–7)

Hematologic Malignancies

• 42458108 [7] Blood Res — Asciminib first-line CML systematic review (8 studies, >500 pts): ASC4FIRST Phase 3 shows MMR 74.1% vs 52.0% for TKIs at 96 weeks; lower discontinuation rate (5% vs 12.7%). Supports asciminib as preferred first-line CML option.
• 42457877 [7] Leukemia — DNA methylation distinguishes ENKTL from nodal TNKL via MeDIP-seq on FFPE samples; two ENKTL subgroups with distinct OS linked to global methylation/TP53/CNV status. Enables epigenetic-based risk stratification.
• 42458006 [5] Ann Hematol — Peripheral blood CD8+ T-cell count predicts R-CHOP-treated DLBCL prognosis; a CBC-accessible prognostic parameter potentially supplementing IPI.
• 42458174 [5] Drug Saf — Safety and management review of targeted therapies (BTKi, BCL-2i, PI3Ki) for relapsed/refractory CLL; practical clinical guidance.

Early Cancer Detection

• 42455535 [7] JAMA — 2025 Consensus guidelines endorse HPV self-collected vaginal samples for cervical cancer screening, removing access barriers for under-screened populations.
• 42458480 [5] Cell Commun Signal — Exosomal aminopeptidase N (APN/CD13) as liquid biopsy marker for gastric cancer diagnosis and monitoring; translational stage.
• 42455511 [5] FASEB J — Circulating beta3-adrenoreceptor as novel independent biomarker for neuroblastoma risk assessment; liquid biopsy approach for rare pediatric cancer.

AI/ML Diagnostics

• 42458456 [5] BMC Med Inform Decis Mak — Systematic review of contrastive XAI in healthcare; highlights limited clinical validation and standardization gaps in an emerging AI explainability paradigm.

Precision Oncology

• 42458320 [6] BMC Cancer — Meta-analysis (n=13,641) shows HR repair axis positivity associated with reduced breast cancer mortality (HR=0.508, I²=0%), independent of PARPi; PARP1 mRNA prognostic role inconclusive.

Novel Therapeutics

• 42458463 [7] J Transl Med — XNW5004 EZH2 inhibitor enhances anti-tumor immunity and synergizes with PD-1 blockade in lung adenocarcinoma via STING-TBK1-NF-κB/MHC-I axis; preclinical but mechanistically compelling.
• 42458439 [6] BMC Med — Real-world serplulimab+chemotherapy for ES-SCLC (n=635): median OS 17.2 months, ORR 69%—validates ASTRUM-005 trial in routine practice via MAIC analysis.
• 42458329 [5] BMC Cancer — Meta-analysis (10 studies, n=609): fruquintinib+PD-1 in advanced CRC shows descriptive OS 15.7 months/DCR 74%; no comparator—limits conclusions on added PD-1 benefit.

Cardiovascular/Metabolic

• 42455418 [7] Cardiovasc Toxicol — GLP-1 agonist systematic review for doxorubicin cardiotoxicity (13 rodent studies): 7-20% LV EF preservation; no human studies—hypothesis-generating only. Important for cardio-oncology given GLP-1 drug class expansion.
• 42458277 [6] BMC Gastroenterol — GLP-1 RA use and pancreatic outcomes in chronic pancreatitis patients; real-world safety data for a clinically important prescribing concern.
• 42458197 [4] High Blood Press Cardiovasc Prev — Exploratory CV risk modeling for oral GLP-1 agonist orforglipron using PREVENT equations; post-hoc, hypothesis-generating.

Aging/Longevity

• 42455572 [7] JAMA Netw Open — Salivary cortisol patterns linked to cognitive decline in 3,895 diverse older adults (11-year follow-up); racial disparities in diurnal rhythm suggest structural stress embedding.
• 42455656 [7] Aging Cell — 20-protein plasma proteomics mortality score achieves C-index 0.81 in older adults—outperforming metabolomics (0.77) and clinical models (0.73)—with external validation.
• 42455900 [7] Sci Transl Med — Long-term ICMS safety and efficacy in 5 SCI patients over 2-10 years (168M+ pulses, zero serious AEs, 64% electrodes still functional at 10 years); landmark neuromodulation safety data.

Rare Diseases

• 42457680 [7] Nat Commun — SIRT5-SUCLG2 desuccinylation axis delays ovarian aging via mitochondrial-epigenetic crosstalk; ovarian gene therapy with SUCLG2 mutant ameliorates aging in vivo. Relevant to premature ovarian insufficiency.
• 42455293 [7] Endocr Rev — Comprehensive review of genetic/environmental drivers of rare pituitary disorders (congenital pituitary hormone deficiency, SOD, HPE); informs genomic diagnostics and gene therapy targets.
• 42457194 [6] Respirology — 130-patient, 20-year PAP cohort across 3 countries: inhaled GM-CSF as effective as WLL; pulmonary fibrosis predicts treatment failure. Practice-guiding for this rare disease.
• 42454984 [6] J Inherit Metab Dis — Review of urea cycle functional assays in preclinical models; methodological guidance for rare UCD gene therapy development.
• 42453535 [6] Healthc Technol Lett — Explainable ensemble learning with stain normalization for ALL classification from blood smears; XAI approach for hematology automation.
• 42456241 [5] Clin Imaging — AI for hantavirus pulmonary syndrome chest imaging: addresses data scarcity and rare-disease AI challenges.
• 42455252 [5] Dermatol Ther — First European consensus management recommendations for Darier disease (rare ATP2A2 keratinization disorder).
• 42455511 [5] FASEB J — Circulating beta3-adrenoreceptor as novel independent neuroblastoma risk biomarker.

🔵 Sentinel Scan Summary

346 total results | 10 candidates reviewed | 0 HIGH, 1 MEDIUM

The sentinel scan (broad Phase 3/RCT/validation/guideline query) returned mostly articles already captured by topic watchlists. The highest-scoring sentinel-unique candidate:

• 42458499 [4] AIDS Res Ther — Real-world BIC/FTC/TAF outcomes in 1,148 Turkish HIV patients at 12 months; confirms trial effectiveness/tolerability in routine practice.

Other sentinel candidates (orthopaedic surgery, substance use disorder, esophageal radiotherapy adjuvant, harm reduction) were off-topic for the Pulse watchlist and scored ≤4.

🏷️ Topic Flag Summary

📌 Key Themes for 2026-07-16

1. AML biology gets a new oncogenic axis — PAPOLA-mediated hyperactive polyadenylation as a therapeutic target (cordycepin) with Nature Cancer validation.
2. Agentic AI enters radiology — RadFabric demonstrates a modular, interpretable framework surpassing prior CXR models in NPJ Digital Medicine.
3. CAR-T manufacturing innovation — NIH 3-day trispecific CAR-T from whole blood: stem-like phenotype, equivalent cytotoxicity, lower cost/time.
4. Gene therapy milestone — Marnetegragene autotemcel first FDA approval for LAD-I (March 2026) marks lentiviral HSC gene therapy coming-of-age for rare primary immunodeficiencies.
5. ML in CBC diagnostics validated in RCT — SmartAlert 15% reduction in repetitive CBC testing in NEJM AI RCT; implementation roadmap for lab ML-CDS.
6. GLP-1 cardioprotection needs human trials — Systematic review of GLP-1 in doxorubicin cardiotoxicity: consistent preclinical signal (~10-20% LV EF improvement) but zero human data; urgent translational gap.
7. Ovarian aging targeted via mitochondrial-epigenetic crosstalk — SIRT5-SUCLG2 axis in Nature Communications with gene therapy proof-of-concept, relevant to premature ovarian insufficiency.

Generated by Friday (OpenClaw PubMed Pipeline v1.3) | Run: 2026-07-16-attempt1-20260716T090000Z | Attempt 1 of 3